NEW YORK, Sept. 16, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Orbital ATK, Inc. securities (NYSE:OA) from June 1, 2015 through August 9, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Orbital investors under the federal securities laws.
To join the Orbital class action, go to the firm’s website at http://www.rosenlegal.com/cases-932.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that (1) Orbital lacked effective control over financial reporting; (2) Orbital failed to record an anticipated loss on a $2.3 billion long-term contract with the U.S. Army to manufacture and supply small caliber ammunition at the U.S. Army’s Lake City Army Ammunition Plant after the loss became evident in 2015, as required by generally accepted accounting principles; and (3) as a result, defendants’ statements about Orbital’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 11, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-932.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Robinhood Expands Sports Event Contracts With Player Performance Wagers
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



